Ostrowski M J, Jackson A W
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):1803-7.
The effect of polyestradiol phosphate (Estradurin), a long-acting estrogen preparation given im, was assessed in 24 elderly postmenopausal patients with stage II or III primary or recurrent breast carcinoma. Although the drug has been available for many years, there has been no report in the literature of its use in treating breast carcinoma. The results of this study show that a total of 17 of 24 (70.8%) patients had evidence of tumor regression lasting a minimum of 3 months, while in 14 (58.3%) patients regression was maintained for greater than or equal to 6 months. Seven patients had complete (100%) tumor regression. Side effects were almost nonexistent and the agent has been shown to be effective, with good patient acceptability and guaranteed administration. It could be considered as an alternative to oral estrogen therapy where patient compliance is poor and gastrointestinal side effects are severe enough that patients often request a change of treatment.
对24例患有II期或III期原发性或复发性乳腺癌的绝经后老年患者评估了肌肉注射长效雌激素制剂聚磷酸雌二醇（Estradurin）的效果。尽管该药物已上市多年，但文献中尚无其用于治疗乳腺癌的报道。本研究结果显示，24例患者中有17例（70.8%）有肿瘤消退迹象，持续至少3个月，而14例（58.3%）患者的消退持续6个月或更长时间。7例患者肿瘤完全（100%）消退。副作用几乎不存在，且该药物已被证明有效，患者接受度良好且给药有保障。在患者依从性差且胃肠道副作用严重到患者常要求更换治疗方法的情况下，它可被视为口服雌激素治疗的替代方法。
